OBJECTIVES To assess the state of the art of Mexican pharmacoeconomics (PE) and outcomes research (OR) poster presentations at International Society for Pharmacoeconomics and Outcomes Research(ISPOR) meetings, regarding methodological quality and current tendencies. METHODS Systematic review of Mexican presentations on PE and OR at ISPOR Meetings from May 2003 (first Mexican poster presentation) to November 2008. We searched abstracts and poster presentations at Annual International Meetings, Annual European Congresses and Latin America Conferences. Two health economist reviewers assessed the relevance of retrieved abstracts, described the methods of included studies and extracted data that was summarized by consensus. Drummond's criteria were used: a) to classify between complete economic evaluation (CEE) or partial economic evaluation; and b) to assess the criteria quality of methodology. Abstracts characteristics analyses were conducted with descriptive and analytic statistics. RESULTS A total of 116 abstracts matched inclusion criteria: 97 were PE (83.6%), 13 were OR (11.2%) and 6 were clinical trials results (5.2%). A total of 82.5% of PE abstracts were CEE. During the past two years presentations increased significantly(16 studies), showing an 88.9% growth. A total of 60.3% of studies were performed at the Social Security Mexican Institute(IMSS) and 70.1% of PE presentations corresponded to cost-effectiveness analyses. Posters covered a wide range of conditions, with emphasis on cardiovascular diseases (19.8%) and oncology (12.1%). Regarding quality of CEE studies: 27.4% didn't mention study perspective, 40.3% didn't report analyses, 39.1% didn't report discount rate when it was necessary(time horizon above 1-year) and only 52.6% studies estimated an ICER. A total of 69.0% of these studies had a pharmaceutical-industry sponsor, 34.5% were performed by Mexican private consultants and 67.6% of the CEE presentations used a decision tree-model or a Markov model. CONCLUSIONS An increase of Mexican presentations at ISPOR meetings mainly promoted by local consultants and pharmaceutical companies with a medium methodological quality.